For research and educational purposes only. Not medical advice.
Insulin glulisine Reference
Educational, not medical advice reference for Insulin glulisine: Hormonal, Metabolic; regulatory status, evidence posture, source review, and schedule notes.…
Reference summary
Insulin glulisine is a label-verified rapid-acting insulin analog with onset within ~15 minutes, peak ~1 hour, and duration ~2 to 4 hours per label. pepSmart surfaces label-reference content only.
- Categories
- Hormonal, Metabolic
- Aliases
- Apidra, Apidra SoloStar, Rapid-acting insulin analog
- Evidence posture
- human - Prescription insulin. Severe hypoglycemia risk - incorrect dosing can be fatal. Not a research compound. Clinician-directed individualized titration is the only safe use.
- Regulatory status
- FDA-approved prescription medication (Apidra). Initial US approval 2004. Indicated for glycemic control in adults and children with type 1 or type 2 diabetes. Prescription-only. Approved for both subcutaneous administration and intravenous use under specific clinical-care settings per label.
- Content review status
- label verified